JP2010540660A - 哺乳類内の赤血球生成を刺激する新規の組成物および方法 - Google Patents

哺乳類内の赤血球生成を刺激する新規の組成物および方法 Download PDF

Info

Publication number
JP2010540660A
JP2010540660A JP2010528167A JP2010528167A JP2010540660A JP 2010540660 A JP2010540660 A JP 2010540660A JP 2010528167 A JP2010528167 A JP 2010528167A JP 2010528167 A JP2010528167 A JP 2010528167A JP 2010540660 A JP2010540660 A JP 2010540660A
Authority
JP
Japan
Prior art keywords
antibody
hvem
agonist
mammal
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010528167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540660A5 (enExample
Inventor
タマダ，コウジ
チャン，リーピング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2010540660A publication Critical patent/JP2010540660A/ja
Publication of JP2010540660A5 publication Critical patent/JP2010540660A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2010528167A 2007-10-05 2008-10-03 哺乳類内の赤血球生成を刺激する新規の組成物および方法 Pending JP2010540660A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99781807P 2007-10-05 2007-10-05
PCT/US2008/078769 WO2009046313A2 (en) 2007-10-05 2008-10-03 Novel compositions and methods for stimulating erythropoiesis in a mammal

Publications (2)

Publication Number Publication Date
JP2010540660A true JP2010540660A (ja) 2010-12-24
JP2010540660A5 JP2010540660A5 (enExample) 2011-11-17

Family

ID=40526962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010528167A Pending JP2010540660A (ja) 2007-10-05 2008-10-03 哺乳類内の赤血球生成を刺激する新規の組成物および方法

Country Status (5)

Country Link
US (1) US20100203047A1 (enExample)
EP (1) EP2195344A4 (enExample)
JP (1) JP2010540660A (enExample)
CA (1) CA2701608A1 (enExample)
WO (1) WO2009046313A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018537956A (ja) * 2015-10-06 2018-12-27 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
US11634489B2 (en) 2017-08-03 2023-04-25 Alector Llc Anti-TREM2 antibodies and methods of use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9057731B2 (en) * 2010-06-23 2015-06-16 University Of Louisville Research Foundation, Inc. Methods and kits for predicting a response to an erythropoietic agent

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001524985A (ja) * 1997-05-12 2001-12-04 スミスクライン・ビーチャム・コーポレイション ヒト腫瘍壊死因子受容体様２（ｔｒ２）抗体
JP2002544123A (ja) * 1999-04-14 2002-12-24 スミスクライン・ビーチャム・コーポレイション エリトロポイエチン受容体抗体
WO2003086301A2 (en) * 2002-04-12 2003-10-23 Human Genome Sciences, Inc. Antibodies that specifically bind to tr2
WO2007001459A2 (en) * 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
WO2007120766A2 (en) * 2006-04-14 2007-10-25 Amgen Inc. Erythropoietin receptor agonists
JP2008519599A (ja) * 2004-11-12 2008-06-12 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
WO2008145754A2 (en) * 2007-06-01 2008-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Ligands of hvem for treating hematologic malignancies and autoimmune diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
EP1336619A3 (en) * 2002-02-19 2003-12-10 Millenium Pharmaceuticals, Inc. Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
JP2006512391A (ja) * 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001524985A (ja) * 1997-05-12 2001-12-04 スミスクライン・ビーチャム・コーポレイション ヒト腫瘍壊死因子受容体様２（ｔｒ２）抗体
JP2002544123A (ja) * 1999-04-14 2002-12-24 スミスクライン・ビーチャム・コーポレイション エリトロポイエチン受容体抗体
WO2003086301A2 (en) * 2002-04-12 2003-10-23 Human Genome Sciences, Inc. Antibodies that specifically bind to tr2
JP2008519599A (ja) * 2004-11-12 2008-06-12 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
WO2007001459A2 (en) * 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
WO2007120766A2 (en) * 2006-04-14 2007-10-25 Amgen Inc. Erythropoietin receptor agonists
WO2008145754A2 (en) * 2007-06-01 2008-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Ligands of hvem for treating hematologic malignancies and autoimmune diseases

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6013041045; Ｊｕｎｇ　Ｈ．　Ｗ．　ｅｔ　ａｌ: Ｅｘｐ．　Ｍｏｌ．　Ｍｅｄ． Ｖｏｌ．　３５，　Ｎｏ．　６, 200312, ｐ．　５０１-５０８ *
JPN6013041047; Ｗｈｉｔｅｂｅｃｋ　ｅｔ　ａｌ: Ｊｏｕｒｎａｌ　ｏｆ　Ｖｉｒｏｌｏｇｙ Ｖｏｌ．　７５，　Ｎｏ．　１, 200101, ｐ．　１７１-１８０ *
JPN6013041049; Ｘｕ　ｅｔ　ａｌ: Ｂｌｏｏｄ Ｖｏｌ．　１０９，　Ｎｏ．　９, 20070501, ｐ．　４０９７-４１０４ *
JPN6013041052; Ｈａｒｒｏｐ　ｅｔ　ａｌ: Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．　１６１, 1998, １７８６-１７９４ *
JPN6013041054; Ｍｏｒｅｌ　ｅｔ　ａｌ: Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．　１６５, 2000, ｐ．　４３９７-４４０４ *
JPN6013041056; Ｌｅｅ　ｅｔ　ａｌ: Ｊ　Ｂｉｏｌ　Ｃｈｅｍ Ｖｏｌ．　２７１，　Ｎｏ．　１７, 19960426, ｐ．　１０４０５-１０４１２ *
JPN6013041059; Ｇａｌｓｏｎ　ｅｔ　ａｌ: Ｍｏｌ　Ｃｅｌｌ　Ｂｉｏｌ Ｖｏｌ．　１５，　Ｎｏ．　４, 199504, ｐ．　２１３５-２１４４ *
JPN6013041063; Ｃｏｎｎｏｌｌｙ　ｅｔ　ａｌ: Ｊｏｕｒｎａｌ　ｏｆ　Ｖｉｒｏｌｏｇｙ Ｖｏｌ．　７６，　Ｎｏ．　２１, 200211, ｐ．　１０８９４-１０９０４ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018537956A (ja) * 2015-10-06 2018-12-27 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
JP7725185B2 (ja) 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
US11634489B2 (en) 2017-08-03 2023-04-25 Alector Llc Anti-TREM2 antibodies and methods of use thereof

Also Published As

Publication number Publication date
EP2195344A2 (en) 2010-06-16
WO2009046313A2 (en) 2009-04-09
EP2195344A4 (en) 2011-07-06
CA2701608A1 (en) 2009-04-09
WO2009046313A3 (en) 2009-05-22
US20100203047A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
US20240132603A1 (en) Ccr8 antibody and application thereof
US5705157A (en) Methods of treating cancerous cells with anti-receptor antibodies
CN114341189A (zh) 全新il-15前药及其应用
JP6955721B2 (ja) ＲＧＭａ結合タンパク質及びその使用
JP3225493B2 (ja) エリトロポエチン受容体を活性化する抗体
JP6797810B2 (ja) Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法
AU2022350407B2 (en) Interleukin-2 mutant and fusion protein thereof
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
EA009746B1 (ru) ВАРИАНТЫ УЧАСТКА Fc
EA010350B1 (ru) Антитела против cd3 и способы их применения
EA023665B1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
US20210388100A1 (en) Compositions and methods regarding engineered and non-engineered gamma delta t-cells for treatment of hematological tumors
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
US20210388109A1 (en) Compositions and methods regarding engineered and non-engineered gamma delta t-cells for treatment of solid tumors
JP2010540660A (ja) 哺乳類内の赤血球生成を刺激する新規の組成物および方法
KR20250109195A (ko) 에리트로포이에틴 수용체의 합성 항체 작용제
CN119604764A (zh) 免疫调节剂的筛选和制备方法
EP4650368A1 (en) Tetravalent agonists of erythropoietin receptor
CN118271438B (zh) 抗cgrp抗体或其抗原结合片段及其用途
US20250277038A1 (en) Anti-pd-l1 antibody and use thereof
WO2024096022A1 (ja) 抗アディポネクチン受容体抗体及びその利用
CN118525035A (zh) 抗cldn18.2和4-1bb的双特异性抗原结合蛋白及其用途
JP2018515437A (ja) 抗ｃｄ２０／抗ｂａｆｆ二重特異性抗体
BR112017022994B1 (pt) Anticorpo anti-RGMa isolado, molécula de ácido nucleico, vetor recombinante e composição farmacéutica compreendendo o mesmo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140724

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141028